Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257977 | 0.98 | POLB (0.56) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL3759571 | 0.90 | POLB (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL350551 | 0.79 | POLB (0.50) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Doxecitine SCHEMBL6066348 | 0.79 | POLB (0.69) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1274297 | 0.79 | POLG (0.72) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 0.79 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL29030090 | 0.79 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1615548 | 0.79 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 0.79 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 0.79 | POLB (0.78) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113573736-B | Modified micrornas and their use in the treatment of cancer | 纽约州州立大学研究基金会 | 2025-03-25 | — | — | CN | disclosed |
| EP-3359163-B1 | COMBINATION THERAPY | NuCana plc (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230132256-A1 | COMBINATION THERAPY | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2023-04-27 | — | — | US | disclosed |
| WO-2022248268-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2022-12-01 | — | — | WO | disclosed |
| US-20220323475-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2022-10-13 | — | — | US | disclosed |
| CN-113573736-A | Modified microRNAs and their use in the treatment of cancer | 纽约州州立大学研究基金会 | 2021-10-29 | — | — | CN | disclosed |
| EP-3820478-A1 | COMBINATION THERAPY | ADC Therapeutics SA (CH) | 2021-05-19 | — | — | EP | disclosed |
| CN-112367999-A | Combination therapy | ADC治疗有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2020-08-27 | — | — | US | disclosed |
| US-10660912-B2 | Combination therapy for cancer | NuCana plc (GB) | 2020-05-26 | — | — | US | disclosed |
| WO-2020011724-A1 | COMBINATION THERAPY | ADC THERAPEUTICS SA (CH) | 2020-01-16 | — | — | WO | disclosed |
| US-20180271889-A1 | COMBINATION THERAPY FOR CANCER | NuCana plc (GB) | 2018-09-27 | — | — | US | disclosed |
| WO-2017060661-A1 | COMBINATION THERAPY | NUCANA BIOMED LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| US-20160058793-A1 | Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer | TERMAN DAVID S (US) | 2016-03-03 | — | — | US | disclosed |
| US-8388966-B2 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20090004200-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20060140962-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2006-06-29 | — | — | US | disclosed |
| EP-1372717-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030091574-A1 | Combination treatment of pancreatic cancer | CANCER ADVANCES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002076499-A2 | COMBINATION TREATMENT OF PANCREATIC CANCER | APHTON CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132256-A1 | COMBINATION THERAPY | IL2RA, IL2, CD22 | POLG 1925/4885POLB 3212/4885P2RY2 1253/4885 |
| US-10660912-B2 | Combination therapy for cancer | TYMP, PNP, NUCB2 | POLG 29/4885POLB 81/4885P2RY2 1169/4885 |
| US-20180271889-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, NUCB2 | POLG 29/4885POLB 81/4885P2RY2 1169/4885 |
| US-20200268783-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, ENTPD5 | POLG 57/4885POLB 148/4885P2RY2 1114/4885 |
| US-20220323475-A1 | COMBINATION THERAPY FOR CANCER | TYMP, PNP, ENTPD5 | POLG 57/4885POLB 148/4885P2RY2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.